Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of contrast-induced nephropathy after angiography
IRCT20250701066324N1Phase 3Completed
- Sponsor
- Islamic Azad University
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in contrast-induced nephropathy (CIN) comparing Empagliflozin with Placebo (2 arms). Primary endpoint: Changes in serum creatinine levels. Started Jul 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20250701066324N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250701066324N1.